| Product Code: ETC12629513 | Publication Date: Apr 2025 | Updated Date: Dec 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
In 2024, Brunei continued to rely on key exporting countries such as Malaysia, Singapore, Ireland, USA, and Australia for large molecules drug substance CDMO imports. Despite a high Herfindahl-Hirschman Index indicating concentration, the industry saw a significant decline with a CAGR of -12.32% from 2020 to 2024. The growth rate plummeted by -57.43% in 2024, highlighting challenges faced by the market. It is crucial for stakeholders to monitor these trends closely and adapt strategies to navigate the changing landscape effectively.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Brunei Large Molecules Drug Substance CDMO Market Overview |
3.1 Brunei Country Macro Economic Indicators |
3.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Brunei Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Brunei Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2021 & 2031F |
3.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
3.7 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.8 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Brunei Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Brunei Large Molecules Drug Substance CDMO Market Trends |
6 Brunei Large Molecules Drug Substance CDMO Market, By Types |
6.1 Brunei Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2021 - 2031F |
6.1.3 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021 - 2031F |
6.1.4 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2021 - 2031F |
6.1.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2021 - 2031F |
6.1.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2021 - 2031F |
6.1.7 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2021 - 2031F |
6.2 Brunei Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.2.3 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2021 - 2031F |
6.2.4 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2021 - 2031F |
6.2.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2021 - 2031F |
6.2.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2021 - 2031F |
6.3 Brunei Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2021 - 2031F |
6.3.3 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021 - 2031F |
6.3.4 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021 - 2031F |
6.3.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2021 - 2031F |
6.3.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2021 - 2031F |
6.4 Brunei Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2021 - 2031F |
6.4.3 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2021 - 2031F |
6.4.4 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2021 - 2031F |
6.4.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2021 - 2031F |
6.4.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2021 - 2031F |
6.5 Brunei Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5.3 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2021 - 2031F |
6.5.4 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.5.5 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2021 - 2031F |
6.5.6 Brunei Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2021 - 2031F |
7 Brunei Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Brunei Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Brunei Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Brunei Large Molecules Drug Substance CDMO Market Key Performance Indicators |
9 Brunei Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Brunei Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2021 & 2031F |
9.2 Brunei Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2021 & 2031F |
9.3 Brunei Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2021 & 2031F |
9.4 Brunei Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
9.5 Brunei Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Brunei Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Brunei Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Brunei Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here